Currently, retatrutide is in phase 3 trials that could be released by the end of 2025
Standard dosing is evidence-based, while microdosing, using lower-than-prescribed doses, has gained attention despite limited evidence, with potential benefits offset by concerns about reduced efficacy, safety risks, and lack of clinical validation
Learn how were redefining pharmacy benefits
Peptide Library Our weight management peptides target stubborn fat, regulate appetite, and improve energy balance
Industry guidance from organizations like the FDA and NCBI emphasize the importance of analytical verification, which is incorporated into the standard quality workflow at Iron Labs to provide consistent, high-quality research materials
Sitagliptin was granted FDA approval on 16 October 2006 (National Center for Biotechnology Information, 2023f)